Pharmacy and Specialty Drug Prior Authorization Criteria
Customize your policy alerts
Sign up for all Health Alliance Plan (HAP) policy alerts
Know when Health Alliance Plan (HAP) releases new policies or updates existing guidance.
Monitor payer policy activity
Receive email alerts as soon as relevant payer policies are published or updated.
Establishes prior authorization requirements for selected pharmacy and specialty drugs, including clinical information, prescriber qualifications, prerequisite therapy, coverage duration, and indication requirements.
Policy Summary
PayerHealth Alliance Plan (HAP)
PolicyPharmacy and Specialty Drug Prior Authorization Criteria
Policy CodePolicy N/A
Change TypeNo material change
Effective DateN/A
Next Review DateN/A
Key ActionSubmit the diagnosis, prior-treatment history and response, and other required clinical documentation with each applicable prior authorization request.
No material clinical or coverage changes in this revision.
15Products listed in the provided excerpt
2Required prior trials for selected MDD therapies
BRCA-mutated mCRPCAkeega disease criterion
5 yearsLongest listed authorization duration
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.
Drug Coverage Criteria
Product-Level Coverage Criteria
Covered when the product-specific diagnosis, documentation, prescriber, prerequisite, exclusion, age, and duration requirements below are met.
ARALAST NP, GLASSIA, PROLASTIN-C IV, ZEMAIRA
Diagnosis of severe congenital A1-PI deficiency with clinically evident emphysema; submit weight, A1-PI phenotype, and baseline A1-PI level.
Prescription written by a pulmonologist.
Coverage duration: 1 year.
ACTIMMUNE
Beneficiary is of an appropriate age according to FDA prescribing information.
Prescribed by a hematologist, oncologist, immunologist, infectious-disease specialist, or endocrinologist.
Diclofenac sodium topical gel 3%
Beneficiary is of an appropriate age according to FDA prescribing information.
Prior use of topical fluorouracil 5% and topical imiquimod, unless contraindicated.
Adapalene topical products
Diagnosis, previous treatments, and response are documented.
Failure, intolerance, or contraindication to tretinoin.
Not approved for photoaging.
Coverage duration: 1 year.
ADBRY
Atopic dermatitis with prior trial of at least one topical corticosteroid and at least one topical immunomodulator.
Appropriate age per FDA prescribing information.
Prescribed by an allergist, immunologist, pulmonologist, otolaryngologist, or dermatologist.
Coverage duration: 1 year.
ADEMPAS
Diagnosis and required prior therapies are documented.
Required prerequisite therapy must be satisfied.
Everolimus antineoplastic
Diagnosis documented.
Prescribed by an oncologist or neurologist.
Coverage duration: 5 years.
AKEEGA
Metastatic castration-resistant prostate cancer with deleterious or suspected deleterious BRCA mutation.
Beneficiary is of an appropriate age per FDA prescribing information.
Prescribed by an oncologist or urologist.
Coverage duration: 5 years.
ALECENSA, XALKORI, ZYKADIA
Diagnosis documented.
Prescribed by an oncologist.
Coverage duration: 5 years.
ALUNBRIG
Metastatic NSCLC that is ALK-positive by an approved test.
Prescribed by or in consultation with an oncologist.
Continuation requires response to prior therapy.
Coverage duration: 5 years.
FIRDAPSE (amifampridine)
Documented Lambert-Eaton myasthenic syndrome, confirmed with electrodiagnostic studies including repetitive nerve stimulation and anti-P/Q-type VGCC antibody testing.
Prescribed by a neurologist.
Coverage duration: 1 year.
Armodafinil and modafinil
Beneficiary is of an appropriate age per FDA prescribing information.
For adjunctive treatment of adult depression, document diagnosis and treatment rationale.
AUVELITY, FETZIMA, TRINTELLIX, vilazodone
Diagnosis and prior therapies are documented.
For MDD, failure of two generic antidepressants from different classes, or rationale alternatives are unsuitable.
Coverage duration: 5 years.
Atypical antipsychotics
Diagnosis and treatment history documented.
Beneficiary is of an appropriate age per FDA prescribing information.
For schizophrenia, failure of two generic atypical antipsychotics or documented rationale alternatives are unsuitable; for MDD, failure of a generic antidepressant combined with quetiapine, olanzapine, or aripiprazole.
Coverage duration: 3 years.
Aprepitant
For highly or moderately emetogenic chemotherapy, submit the chemotherapy regimen, including drug, dose, and frequency.
For postoperative nausea/vomiting prophylaxis, ondansetron is preferred; submit rationale why ondansetron is inappropriate when aprepitant is requested.
Request is reviewed for Part B versus Part D coverage.
Coverage duration: 6 months.
ARCALYST
Beneficiary is of an appropriate age according to FDA prescribing information.
Coverage approved 1 year at a time.
ARIKAYCE
Confirmed MAC lung disease supported by medical records and sputum culture.
For initial review, failure to obtain negative sputum cultures after at least 6 months of multidrug background therapy for MAC lung disease.
Prescribed by or in consultation with an infectious-disease specialist or pulmonologist.
Beneficiary is of an appropriate age per FDA prescribing information; coverage duration: 1 year.
ATTRUBY
Diagnosis confirmed by appropriate testing.
Prescription written by a cardiologist.
Coverage duration: 1 year.
AUGTYRO
Beneficiary is of an appropriate age according to FDA prescribing information.
AVMAPKI-FAKZYNJA
Diagnosis documented.
Prescription written by an oncologist.
Coverage duration: 5 years.
AYVAKIT
Diagnosis documented and beneficiary is of an appropriate age per FDA prescribing information.
For GIST, document PDGFRA exon 18 or PDGFRA D842V mutation.
For advanced systemic mastocytosis, document platelet count greater than 50 × 10^9/L.
Prescribed by an oncologist or gastroenterologist, or an allergist/immunologist as appropriate.
Diagnosis documented and beneficiary meets FDA age requirements.
Specialist prescribing and product-specific treatment documentation required.
CAPRELSA
Diagnosis documented and prescribed by an oncologist.
No history of congenital long QT syndrome.
ECG, potassium, magnesium, calcium, and TSH monitoring at baseline, 2–4 weeks, 8–12 weeks, and every 3 months thereafter.
CINQAIR
Severe asthma diagnosis; currently receiving inhaled and/or oral corticosteroid therapy; baseline eosinophil count documented.
Submit allergen testing, baseline and post-bronchodilator FEV1, asthma history, medications, emergency visits/hospitalizations, and eosinophil count.
Prescribed by pulmonology or immunology.
Administration requires a specialized care setting with an experienced clinician prepared to manage anaphylaxis; self-administration is not covered.
Coverage duration: 1 year.
COBENFY
Diagnosis and treatment history documented.
For schizophrenia, failure of two atypical antipsychotics or rationale alternatives are unsuitable.
CORLANOR and ivabradine
For adult heart failure: EF ≤35%, heart rate ≥70 bpm, sinus rhythm, and maximally tolerated beta-blocker therapy or contraindication to beta-blocker.
Prescribed by a cardiologist; required prerequisite therapy; coverage duration: 12 months.
COSENTYX
Diagnosis, prior treatments and reasons for failure, and baseline and ongoing TB monitoring documented.
For arthritis: trial of or contraindication to one non-biologic DMARD; a prior biologic trial removes the requirement to step back to a traditional agent.
For plaque psoriasis: failure of cyclosporine and methotrexate for at least 3 months.
For hidradenitis suppurativa: trial of one other therapy, such as corticosteroids, systemic antibiotics, or isotretinoin.
Do not combine with another biologic or JAK inhibitor; prescribed by a rheumatologist or dermatologist; coverage duration: 1 year.
Cyclobenzaprine
Diagnosis and medical records documenting the diagnosis are required.
Patients younger than 65 years are approved. For patients aged 65 years or older, additional criteria apply.
Coverage duration: 1 year.
CYSTADROPS
Diagnosis and presence of corneal cystine crystals documented.
Appropriate age per FDA prescribing information.
Prescribed by an ophthalmologist or corneal specialist.
DAYBUE, DUVYZAT, FILSUVEZ, FINTEPLA
Beneficiary is of an appropriate age per FDA prescribing information.
For DUVYZAT, genetically confirmed DMD, baseline function tests, ambulatory status, and specialist involvement are required.
Dronabinol
Diagnosis, prior treatments, and outcomes documented.
Not covered for pain. For cancer-related weight loss, failure or intolerance to megestrol is required.
DUPIXENT
Diagnosis and indication-specific documentation required.
Atopic dermatitis requires topical immunomodulator trial, except patients younger than 2 years; CRS with nasal polyps requires persistent inflammation for at least 12 weeks and intranasal corticosteroid trial; asthma requires eosinophils ≥150 cells/mcL and inhaled corticosteroid plus at least two controller therapies; EoE requires biopsy with ≥15 eosinophils/HPF and persistent symptoms after an 8-week therapy trial; AFRS requires eosinophilic mucin and fungal culture; prurigo nodularis requires documented diagnosis.
Do not combine with another biologic; specialist prescribing and required prerequisite therapy apply.
Enbrel
Diagnosis, concurrent medications, and previous therapies documented; do not combine with another biologic or JAK inhibitor.
RA: failure of Hadlima for at least 3 months; exceptions apply when a prior biologic trial is documented.
Plaque psoriasis and PsA: failure of Hadlima and Yesintek for at least 3 months; pediatric exceptions permitted.
JIA/JRA: aggressive disease, prior agent trial, concurrent MTX/sulfasalazine/leflunomide, or absolute contraindication to those agents.
GVHD: current etanercept with one conventional GVHD treatment; Behçet disease: failure of one conventional treatment or adalimumab/infliximab; uveitis: failure of corticosteroid, immunosuppressive, Hadlima, or infliximab therapy.
Continuation requires clinical response. Additional quantity for 50 mg twice weekly is allowed for plaque psoriasis; RA/JIA/PsA/AS stabilized on 50 mg twice weekly; or at least 50 mg once weekly for 2 months.
ENSACOVE
Beneficiary is of an appropriate age according to FDA prescribing information.
ENVARSUS XR
Beneficiary is of an appropriate age according to FDA prescribing information.
Required prerequisite therapy.
EPIDIOLEX
Diagnosis, prior therapy and outcome documented; continuation requires response.
Lennox-Gastaut syndrome: use of valproate and lamotrigine with failure or intolerance. Dravet syndrome: use of valproate and topiramate with failure or intolerance. Refractory seizures: failure or intolerance of two anticonvulsants from different pharmacologic classes.
Prescribed by or in consultation with a neurologist; coverage duration: 5 years.
EPOGEN and erythropoiesis-stimulating agents—initial therapy
For initial therapy, pretreatment hemoglobin is less than 10 g/dL, iron stores are adequate (ferritin >100 mcg/L or transferrin saturation >20%), and other causes of anemia have been ruled out.
Indication-specific prescriber required: nephrologist/hematologist for CKD, oncologist/hematologist for non-myeloid malignancy, surgeon for surgery, or infectious-disease specialist for HIV.
Exclude uncontrolled hypertension and pure red cell aplasia following ESA treatment; CMS review requirements apply.
EPOGEN and erythropoiesis-stimulating agents—renewal
CKD dialysis: Hb <11 g/dL or physician will decrease/interupt dose; nondialysis: Hb <10 g/dL or physician will decrease/interupt dose.
Non-myeloid malignancy: concurrent myelosuppressive chemotherapy, Hb ≤12 g/dL, and measurable response after 8 weeks.
Zidovudine-treated HIV: Hb ≤12 g/dL, zidovudine ≤4,200 mg/week, and measurable response after 8 weeks.
Coverage duration: 1 year; prescriber restrictions and exclusions continue to apply.
FASENRA
Severe asthma, inhaled and/or oral corticosteroid treatment, and eosinophils ≥150 cells/mcL within the prior 12 months; EGPA requires documented diagnosis.
Submit allergen testing, FEV1 data, asthma history, and eosinophil count.
Do not combine with another biologic; specialist prescribing required; coverage duration: 1 year.
Forteo initial therapy
Osteoporosis diagnosis, fracture history, prior therapy and response, DXA, and required pretreatment laboratory testing documented.
Trial and failure of an oral bisphosphonate, or parenteral bisphosphonate when GI intolerance exists, and trial and failure of denosumab; failure means intolerance, BMD decrease, or new fracture.
Do not combine with another PTH/PTHrP analog or other osteoporosis agent.
Prescribed by an endocrinologist; coverage duration: 2 years.
FOTIVDA
Diagnosis, prior therapy and result documented; continuation requires response to tivozanib.
Appropriate age per FDA prescribing information and required prerequisite therapy.
FRUZAQLA
Metastatic colorectal cancer previously treated with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, an anti-VEGF therapy, and—when RAS wild-type and medically appropriate—an anti-EGFR therapy.
Prescribed by or in consultation with a hematologist or oncologist; coverage duration: 5 years.
FYCOMPA
Diagnosis documented and prescription written by a neurologist.
Monitor for serious psychiatric or behavioral reactions at initiation and after dose escalation; clinical notes documenting psychiatric/behavioral status are required.
Coverage duration: 5 years.
GABARONE
Beneficiary is of an appropriate age per FDA prescribing information.
Intolerance, contraindication, or medical reason preventing use of gabapentin is documented.
Coverage limited to some FDA-approved indications.
GATTEX
Diagnosis, prior therapies, and treatment responses documented.
Adults require complete colonoscopy with polyp removal before initiation; pediatric fecal occult blood testing is required when indicated.
Discontinue for intestinal malignancy; prescribed by a gastroenterologist; coverage duration: 3 years.
CERDELGA and miglustat
Diagnosis documented; not approved for type II or type III Gaucher disease.
Miglustat is reserved for patients for whom enzyme replacement therapy is not an option, with rationale submitted.
Prescribed by a geneticist, hematologist, hepatologist, or metabolic specialist; coverage duration: 3 years.
GAVRETO
NSCLC or thyroid cancer with RET fusion mutation verified by an FDA-approved diagnostic test.
Prescribed by an oncologist or pulmonologist; coverage duration: 5 years.
GLP-1 products / TRULICITY
Documented type 2 diabetes and A1C from the prior 6 months.
Not covered for weight loss. Cardiovascular-risk initiation additionally requires ASCVD or high cardiovascular risk and required prior therapy.
Coverage duration: 1 year.
Hepatitis C treatment / MAVYRET
Submit patient weight, genotype, HCV RNA, fibrosis level, and treatment history.
Prescribed by a hepatologist or infectious-disease specialist.
Duration is 8–24 weeks and approval follows current AASLD-IDSA guidance.
HAEGARDA, icatibant, SAJAZIR
Confirmed hereditary angioedema diagnosis and appropriate age.
Icatibant initiation: age 18 or older; continuation requires favorable clinical response to prior acute attacks.
Haegarda initiation: age 6 or older.
Prescribed by an allergist or immunologist; injectable and oral HAE prophylaxis may not be duplicated.
INBRIJA
Parkinson disease diagnosis, prior therapy and response documented; continuation requires response to levodopa inhalation.
Failure of both carbidopa/levodopa immediate- and extended-release and at least one other Parkinson disease drug.
Prescription written by a neurologist; coverage duration: 3 years.
IMPAVIDO
Leishmaniasis diagnosis documented; appropriate age and specialist involvement required.
The following exclusions and prohibitions apply in addition to product-specific criteria: photoaging treatment with adapalene is not covered; Caprelsa is not covered with a history of congenital long QT syndrome; dronabinol is not covered for pain and Trulicity is not covered for weight loss; biologics and JAK inhibitors must not be combined where stated; Cinqair reslizumab is not approved for self-administration; Cosentyx, Enbrel, and other specified biologics must not be combined with another biologic or JAK inhibitor; dual injectable and oral HAE prophylaxis is not covered; Diacomit monotherapy for Dravet syndrome is not supported; Erivedge is not covered when the patient is a candidate for surgery or radiation; Gattex must be discontinued for intestinal malignancy; Cerdelga/miglustat is not approved for type II or type III Gaucher disease; and PTH/PTHrP analogs must not be combined with other osteoporosis agents.
Unapproved combinations, duplicate prophylaxis, off-label pain or weight-loss use, and unsupported monotherapy are denial risks. Submit diagnosis, prior treatment history, response or intolerance, required laboratory or genetic testing, and the indication-specific prescriber documentation with each request.
Initial Therapy Criteria
Initial therapy is covered when all applicable product-specific requirements are met.
Initial therapy—specialty and orphan products
Document the covered diagnosis and FDA-appropriate age.
Submit all indication-specific testing, laboratory results, prior therapy, treatment response or intolerance, and required specialist prescription.
Satisfy prerequisite therapy and quantity requirements where listed.
Initial therapy—Enbrel
Meet the indication-specific step requirements for RA, psoriasis, PsA, JIA/JRA, GVHD, Behçet disease, or uveitis.
For quantity above the standard limit, document the applicable twice-weekly or stabilized dosing criterion.
Continuation and Renewal Criteria
Continuation or renewal requires the product-specific response, monitoring, and ongoing eligibility documentation.
Continuation—Alunbrig
Document ongoing therapy and clinical benefit/response.
Continuation—Bosulif
Submit response to bosutinib and CBC/LFT results.
Continuation—Enbrel
Document clinical response according to the treating prescriber.
For additional quantity, document the applicable plaque psoriasis, stabilized twice-weekly, or 50 mg once-weekly for at least 2 months criterion.
Continuation—Epidiolex
Product or category
Prerequisite / step requirement
Exception or quantity rule
Adapalene
Failure, intolerance, or contraindication to tretinoin
Photoaging remains excluded
Diclofenac topical gel 3%
Prior topical fluorouracil 5% and imiquimod
Exception when contraindicated
AUVELITY, FETZIMA, TRINTELLIX, vilazodone, EXXUA
Failure of required generic antidepressants
EXXUA requires vilazodone plus another generic antidepressant
BENLYSTA
Failure of two standard therapies
Document diagnosis-specific response
BONSITY / Forteo / teriparatide
Bisphosphonate sequence and required denosumab failure
No combination with other osteoporosis agents
CINQAIR / FASENRA
Severe asthma, corticosteroid therapy, and eosinophil threshold
Cinqair must be administered in a specialized care setting
COSENTYX
Indication-specific DMARD, cyclosporine/methotrexate, or other therapy trial
Every-two-week dosing requires failure of every-four-week dosing
Enbrel
Hadlima; Hadlima plus Yesintek for psoriasis/PsA; or indication-specific conventional therapy
Pediatric and contraindication/aggressive-disease exceptions; additional quantity criteria apply
ERLEADA
Failure, intolerance, or contraindication to abiraterone for specified prostate cancer indications
Prescriber must be oncologist or urologist
Ibrance
Trial of Kisqali or Verzenio
Exception for PIK3CA-mutated HR-positive/HER2-negative advanced breast cancer
INBRIJA
Failure of carbidopa/levodopa IR and ER plus one other Parkinson drug
Continuation requires response
MAVYRET
Treatment follows current AASLD-IDSA guidance
Duration 8–24 weeks based on clinical factors
Dronabinol
Megestrol failure or intolerance for cancer-related weight loss
Prior authorization is required for the products and product groups below. Submit the diagnosis, applicable FDA-label age information, requested duration, and the required prescriber specialty with the PA request.
AAT deficiency: ARALAST NP, GLASSIA, PROLASTIN-C intravenous solution, and ZEMAIRA require documentation of severe congenital A1-PI deficiency with clinically evident emphysema, weight, A1-PI phenotype, and baseline A1-PI level; prescribing must be by a pulmonologist; coverage is 1 year.
ACTIMMUNE: Submit appropriate age confirmation and use a hematologist, oncologist, immunologist, infectious disease specialist, or endocrinologist.
AKEEGA: Submit metastatic castration-resistant prostate cancer with a deleterious or suspected deleterious BRCA mutation and an appropriate age; prescribing must be by an oncologist or urologist; coverage is 5 years.
ALK inhibitors: ALECENSA, XALKORI (capsules and pellets), and ZYKADIA require diagnosis documentation and an oncology prescriber; ALUNBRIG requires metastatic NSCLC that is ALK-positive by an approved test, oncology prescribing or consultation, and continuation documentation when applicable; coverage is 5 years.
FIRDAPSE: Confirm Lambert-Eaton myasthenic syndrome with electrodiagnostic studies, including repetitive nerve stimulation and anti-P/Q-type voltage-gated calcium-channel antibody testing; prescribing must be by a neurologist; coverage is 1 year.
Clinical Thresholds and Required Values
Numeric thresholds and documentation requirements
AdvSM platelet countGreater than 50 X 10-9th/L
Baseline eosinophil count for CinqairRequired; the numeric threshold is not provided in the excerpt
Asthma baseline eosinophil count150 cells/mcL or greater within the previous 12 months
Eosinophilic esophagitis biopsyGreater than or equal to 15 intraepithelial eosinophils per high power field, or 60 eosinophils per mm2
Treatment-duration thresholdsCosentyx plaque psoriasis treatment failure: at least 3 months; topical nasal corticosteroid trial: 4 weeks; eosinophilic esophagitis symptoms must persist after an 8-week trial
Age criterionPatients aged less than 65 years are approved for cyclobenzaprine; patients aged 65 years and older require additional criteria
Terms and Clinical Definitions
Definitions
AAT deficiencySevere congenital alpha-1 proteinase inhibitor deficiency with clinically evident emphysema, supported by A1-PI phenotype and baseline A1-PI level.
Metastatic castration-resistant prostate cancerProstate cancer that has progressed despite castrate-level androgen suppression, with metastasis from a malignant prostate tumor.
MAC lung disease; GIST; and AdvSMMAC lung disease is Mycobacterium avium complex lung disease supported by sputum culture documentation. GIST is the Ayvakit indication requiring a PDGFRA exon 18 or PDGFRA D842V mutation. AdvSM is the Ayvakit indication requiring a platelet count greater than 50 X 10-9th/L.
Treatment failureFor Enbrel, failure means intolerance or inability to improve symptoms. For Forteo/teriparatide, failure means intolerance, a decrease in bone mineral density compared with the previous DEXA scan, or a new fracture; treatment failure is not separately defined for dronabinol in this excerpt.
JAKis and JAK inhibitorJAKis refers to Janus kinase inhibitors; a JAK inhibitor is a Janus kinase inhibitor.
Quantity and Dosing Limits
Quantity limits
Cosentyx induction quantityAllowable quantity depends on the induction dosing regimen for the applicable FDA-labeled indication.
Enbrel 25 mg quantity escalationAdditional quantity may be approved to allow 50 mg twice-weekly dosing for plaque psoriasis; for rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, or ankylosing spondylitis when started and stabilized on 50 mg twice-weekly dosing; or when taking 50 mg once weekly for at least 2 months.
Administration Setting Requirements
Billing Rule
Administer reslizumab in a specialized care setting
Administer Cinqair (reslizumab) in a specialized care setting by an experienced clinician prepared to manage anaphylaxis. Self-administration is not approved and will not support coverage.
Use a specialized care setting, such as an infusion center.
Ensure an experienced clinician is prepared to manage anaphylaxis.
Do not submit or administer the product as self-administered therapy.
Policy Scope
This pharmacy and specialty drug prior authorization policy establishes coverage requirements for selected medications and products across multiple therapeutic areas. Requests generally require documentation of the diagnosis and clinical need, appropriate age under FDA prescribing information, qualified specialist prescribing, prior or prerequisite therapy, treatment response, and any indication-specific laboratory, molecular, or disease-severity evidence.
The excerpt represents a broad range of therapies, including alpha-1 proteinase inhibitor replacement for congenital deficiency with emphysema; dermatologic and atopic-dermatitis therapies; oncology and hematology agents; prostate cancer and other targeted therapies; pulmonary and severe-asthma biologics; neurologic and antiseizure medications; antidepressants and antipsychotics; diabetes and insulin-delivery products; osteoporosis and endocrine therapies; gastrointestinal and intestinal-failure treatments; hepatitis C and anti-infective therapies; hereditary angioedema treatments; and sleep-related therapies. Coverage is generally available only when the applicable product-specific clinical and administrative criteria are satisfied.
Prerequisite Treatment Pathways
Therapeutic area
Products or indications
Step-therapy requirement
Exceptions or failure standard
Topical therapies
Diclofenac sodium topical gel 3%; adapalene; Adbry for atopic dermatitis
Diclofenac: topical 5% fluorouracil plus topical imiquimod. Adapalene: tretinoin. Adbry: at least one topical corticosteroid plus one topical immunomodulator.
Diclofenac permits an applicable exception. Adapalene requires failure, intolerance, or contraindication to tretinoin. Adbry requires prior trials; specific failure language is not stated.
Antidepressants
Auvelity, Fetzima, Trintellix, vilazodone, and Exxua for MDD
Two generic antidepressants from different classes. Exxua specifically requires two trials, including vilazodone.
Trials must be tried and failed; examples include SSRIs, SNRIs, TCAs, bupropion, and venlafaxine.
Antipsychotics
Asenapine, Caplyta, Fanapt, Rexulti, Secuado, Versacloz, Vraylar, and Cobenfy
Trial of two atypical antipsychotics for Cobenfy schizophrenia; listed alternatives include ziprasidone, risperidone, quetiapine, olanzapine, clozapine, and aripiprazole. Other antipsychotic requests require trials of listed alternatives.
Treatment failure is required for Cobenfy. Other requests may use documented rationale explaining why alternatives are unsuitable. MDD requests require an antidepressant combined with quetiapine, olanzapine, or aripiprazole, or rationale.
Biologics and immunomodulators
Benlysta, Besremi, Cosentyx, Dupixent, Enbrel, and Hadlima
Requirements vary: standard therapies before Benlysta; prior therapy before Besremi; DMARDs or disease-specific therapies before Cosentyx; topical, inhaled, nasal, or esophageal therapies before Dupixent; Hadlima and Yesintek before Enbrel for specified indications; DMARDs or disease-specific therapies before Hadlima.
Benlysta requires inadequate response to two standard therapies. Cosentyx plaque psoriasis requires cyclosporine and methotrexate for at least 3 months. Enbrel psoriasis and psoriatic arthritis require Hadlima and Yesintek for at least 3 months, with pediatric exceptions. Hadlima weekly dosing requires failure of every-other-week dosing except for hidradenitis suppurativa.
Oncology agents
Erleada, Fruzaqla, Ibrance, and miglustat for Gaucher disease
Erleada follows abiraterone. Fruzaqla follows fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, anti-VEGF therapy, and anti-EGFR therapy when appropriate. Ibrance follows Kisqali or Verzenio. Miglustat requires enzyme replacement therapy not to be an option.
Erleada permits failure, intolerance, or contraindication to abiraterone. Ibrance has an exception for PIK3CA-mutated HR-positive, HER2-negative locally advanced or metastatic breast cancer. Miglustat requires rationale; Type II and Type III Gaucher disease are excluded.
Osteoporosis therapies
Bonsity; Forteo or teriparatide
Bonsity requires an oral bisphosphonate, or a parenteral bisphosphonate for gastrointestinal intolerance. Forteo or teriparatide requires a bisphosphonate followed by denosumab.
Forteo or teriparatide requires documented failure; failure means intolerance, decreased BMD compared with the prior DEXA scan, or a new fracture. Combination therapy involving a PTH/PTHrP analog and other osteoporosis agents is excluded.
Migraine therapies
Dihydroergotamine nasal
Two different formulary triptans: one oral tablet and one nasal spray or injection.
Both must be tried and failed unless contraindicated.
GLP-1 products
Trulicity and other listed GLP-1 products
Type 2 diabetes documentation and an A1C from the past 6 months. For cardiovascular event-risk initiation, type 2 diabetes plus ASCVD history or high cardiovascular-event risk is required.
Weight-loss use is excluded. The source begins an additional previous-trial requirement for cardiovascular-risk initiation but is truncated.
Neurologic drugs
Banzel, Briviact, Cibinqo, Epidiolex, INBRIJA, and related neurologic products
Prerequisite therapy applies to Banzel, Briviact, and Cibinqo. Epidiolex requires diagnosis-specific prior antiseizure therapies. INBRIJA requires immediate-release and extended-release carbidopa/levodopa plus one additional Parkinson disease drug.
Epidiolex requires failure or intolerance of valproate plus lamotrigine for Lennox-Gastaut syndrome, valproate plus topiramate for Dravet syndrome, or two anticonvulsants from different classes for refractory seizures. INBRIJA requires failure of all specified prerequisite drugs.
Policy Summary
PayerHealth Alliance Plan (HAP)
PolicyPharmacy and Specialty Drug Prior Authorization Criteria
Policy CodePolicy N/A
Change TypeNo material change
Effective DateN/A
Next Review DateN/A
Key ActionSubmit the diagnosis, prior-treatment history and response, and other required clinical documentation with each applicable prior authorization request.
Prescriber must be appropriate to indication; coverage duration: 1 year.
Initial therapy—ESAs
Pretreatment hemoglobin <10 g/dL, adequate iron stores, and exclusion of alternative causes of anemia.
Meet the indication-specific prescriber and CMS requirements.
Initial therapy—Forteo/teriparatide
Document osteoporosis severity, fracture history, DXA and laboratory evaluation.
Document failure of bisphosphonate therapy and denosumab as required.
Initial therapy—Hepatitis C
Submit weight, genotype, HCV RNA, fibrosis, and treatment history.
Treatment must align with current AASLD-IDSA guidance and be prescribed by a hepatologist or infectious-disease specialist.
Document response to treatment.
Continuation—ESAs
Meet indication-specific hemoglobin, ongoing chemotherapy or zidovudine, dose, and measurable-response requirements.
Continuation—Fotivda
Document response to tivozanib.
Continuation—icatibant
Document favorable clinical response, such as shorter attacks, faster relief, complete resolution, or reduced attack frequency/severity.
Continuation—Hetlioz/tasimelteon
For non-24-hour sleep-wake disorder, submit sleep-log and sleep-study documentation; renewal requires increased nighttime sleep and decreased daytime naps.
Continuation—INBRIJA
Document response to levodopa inhalation and intention to continue therapy.
Aprepitant: Submit the chemotherapy regimen, including drug, dose, and frequency, for highly or moderately emetogenic chemotherapy. The request is reviewed for Part B versus Part D; for postoperative nausea/vomiting (PONV), ondansetron is preferred and the request must explain why ondansetron is unsuitable.
ARCALYST: Verify age and the requested indication; coverage is approved 1 year at a time.
ARIKAYCE: Submit medical records and sputum culture confirming MAC lung disease, documentation of failure to obtain negative cultures after at least 6 months of multidrug background therapy, and use by or in consultation with an infectious-disease specialist or pulmonologist; coverage is 1 year.
ATTRUBY: Submit cardiologist prescribing and diagnostic confirmation with appropriate testing; coverage is 1 year.
AUGTYRO: Confirm the beneficiary is of an age appropriate under FDA prescribing information and document the requested indication.
AVMAPKI-FAKZYNJA: Submit diagnosis documentation, age confirmation, and oncology prescribing; coverage is 5 years.
AYVAKIT: Submit diagnosis-specific evidence and use the appropriate specialist: oncologist or gastroenterologist, or allergist or immunologist. For GIST, provide PDGFRA exon 18 or D842V mutation evidence; for AdvSM, provide platelet count greater than 50 × 109/L; coverage is 5 years.
BALVERSA: Submit diagnosis and oncology prescribing; coverage is 5 years.
BENLYSTA: Submit diagnosis, autoantibody testing, prior treatments and responses, and rheumatology or nephrology prescribing; coverage is 3 years.
BESREMI: Confirm age and document intolerance, contraindication, or treatment failure with prerequisite therapy.
BONSITY: Submit diagnosis, fracture history, prior treatment and response, DXA, and required pretreatment calcium, phosphorus, creatinine, alkaline phosphatase, albumin, 25-hydroxyvitamin D, and urine calcium/creatinine testing; prescribing must be by an endocrinologist; coverage is 2 years.
BOSULIF: Submit diagnosis, response to bosutinib, and CBC and liver-function tests for continuation.
BRAFTOVI: Submit diagnosis and oncology prescribing; coverage is 5 years.
BRUKINSA: Confirm age appropriate under FDA prescribing information.
CABOMETYX: Submit diagnosis and oncology oversight by or in consultation with an oncologist; coverage is 5 years.
CALQUENCE: Submit diagnosis documentation and oncology prescribing; coverage is 1 year.
CAPRELSA: Submit diagnosis, age confirmation, oncology prescribing, and baseline and follow-up ECG, potassium, magnesium, calcium, and TSH monitoring. Do not request for a history of congenital long-QT syndrome; monitoring is required at baseline, 2–4 weeks, 8–12 weeks, and every 3 months thereafter; coverage is 5 years.
CIBINQO: Confirm age, diagnosis, and prerequisite therapy.
CINQAIR: Submit severe-asthma records, allergen testing, baseline and post-bronchodilator FEV1, asthma treatment and exacerbation history, and baseline eosinophil count; prescribing must be by pulmonology or immunology; coverage is 1 year.
COBENFY: Submit schizophrenia diagnosis and treatment history; coverage requires failure of two atypical antipsychotics and is authorized for 5 years.
COMETRIQ: Submit diagnosis and oncology prescribing; coverage is 5 years.
COPIKTRA: Submit diagnosis and prescribing by an oncologist or hematologist; coverage is 5 years.
CORLANOR: For adult heart failure, submit ejection fraction ≤35%, heart rate ≥70 bpm, sinus rhythm, and maximally tolerated beta-blocker use or a beta-blocker contraindication; prescribing must be by a cardiologist; coverage is 12 months.
COSENTYX: Submit diagnosis, prior therapies and failures, and TB monitoring at baseline and during treatment; prescribing must be by rheumatology or dermatology; coverage is 1 year.
COTELLIC: Submit diagnosis and oncology prescribing; coverage is 5 years.
CRESEMBA: Confirm age, diagnosis, and prerequisite therapy.
Cyclobenzaprine: Submit diagnosis and medical records; patients younger than 65 are approved, while age 65 and older requires additional criteria; coverage is 1 year.
CYSTADROPS: Submit diagnosis, age, ophthalmologist or corneal-specialist prescribing, and documentation of corneal cystine crystals and photophobia.
DAURISMO: Submit diagnosis and prescribing by an oncologist or hematologist; coverage is 5 years.
DAYBUE: Confirm age appropriate under FDA prescribing information.
Demser/metyrosine: Submit diagnosis and whether the patient is a surgical candidate; coverage is 1 year.
DIACOMIT: Submit indication documentation and confirm it will not be used as monotherapy for Dravet syndrome.
Fidaxomicin: Submit C. difficile diagnosis and use by or in consultation with an infectious-disease specialist; coverage is 1 month.
DOPTELET: Submit diagnosis and platelet count; specialist prescribing is required. For chronic-liver-disease thrombocytopenia, document a planned procedure and timing of treatment 10–13 days before the procedure.
DRONABINOL: Submit diagnosis, prior treatments and outcomes, and megestrol failure or intolerance for cancer-related weight loss; pain is not covered.
DUVYZAT: Submit genetically confirmed DMD, baseline functional testing, age, and specialist documentation; the patient must be ambulatory at initiation; coverage is 1 year.
ENBREL: Submit diagnosis, concurrent medications, prior therapies, and specialty documentation; coverage is 1 year and Part B may apply.
ENSACOVE and ENVARSUS XR: Confirm age appropriate under FDA prescribing information; ENVARSUS XR also requires prerequisite-therapy documentation.
EPIDIOLEX: Submit diagnosis, prior therapy and outcomes, continuation response, and neurologist prescribing or consultation; coverage is 5 years.
EPOGEN and other erythropoiesis-stimulating agents: Submit the indication, hemoglobin, iron stores, exclusion workup, and CMS-required information. Prescriber specialty depends on CKD, malignancy, surgery, or HIV; coverage is 1 year.
EPRONTIA/topiramate oral solution: Submit diagnosis, prior treatment, response, and contraindication information; confirm age and prerequisite therapy.
Dihydroergotamine: Submit diagnosis, prior treatments and responses, and headache-specialist, pain-management, or neurologist prescribing; coverage is 1 year.
ERIVEDGE: Submit diagnosis and oncology or dermatology prescribing; do not approve when the patient is a candidate for surgery or radiation; coverage is 5 years.
ERLEADA: Submit diagnosis, therapies tried and outcomes, fall-risk assessment, and seizure history; oncology or urology prescribing is required; for metastatic CRPC or CSPC, document abiraterone failure, intolerance, or contraindication; coverage is 1 year.
EXXUA: Submit MDD diagnosis and failed generic antidepressants, including vilazodone; coverage is 5 years.
FASENRA: Submit severe-asthma records, allergen testing, FEV1, asthma history, and eosinophil count; prescribing must be by pulmonology, immunology/allergy, or rheumatology; do not combine with another biologic; coverage is 1 year.
FILSUVEZ and FINTEPLA: Confirm age, indication, and applicable clinical documentation.
FORTEO/teriparatide: Submit diagnosis, fracture history, prior therapy and response, DXA and laboratory pretreatment testing, and endocrinology prescribing; coverage is 2 years.
FOTIVDA: Submit diagnosis, prior therapy and outcome, and continuation response to tivozanib.
FRUZAQLA: Submit metastatic colorectal-cancer diagnosis and prior fluoropyrimidine-, oxaliplatin-, irinotecan-, anti-VEGF-, and, when RAS wild-type and appropriate, anti-EGFR-based therapy; hematology/oncology prescribing or consultation is required; coverage is 5 years.
FYCOMPA: Submit diagnosis and neurologist prescribing; document psychiatric and behavioral monitoring at initiation and after dose escalations; coverage is 5 years.
GABARONE: Confirm age and document gabapentin intolerance, contraindication, or medical reason it cannot be used.
GATTEX: Submit diagnosis, prior therapies and responses, gastroenterologist prescribing, and pretreatment evaluation. Adults require complete colonoscopy with polyp removal before initiation; pediatric patients require fecal occult blood evaluation as applicable; coverage is 3 years.
GAUCHER disease treatments: CERDELGA and miglustat require diagnosis and a geneticist, hematologist, hepatologist, or metabolic specialist. Miglustat requires rationale that enzyme-replacement therapy is inappropriate; type II and type III Gaucher disease are excluded; coverage is 3 years.
GAVRETO: Submit NSCLC or thyroid-cancer diagnosis and FDA-approved testing for RET fusion; oncology or pulmonology prescribing is required; coverage is 5 years.
GILOTRIF: Submit diagnosis and oncology prescribing; coverage is 5 years.
GLP-1 diabetes products: For TRULICITY, submit type 2 diabetes diagnosis and A1C from the prior 6 months. Weight-loss use is excluded; cardiovascular-risk initiation also requires ASCVD or high cardiovascular risk and prior therapy documentation; coverage is 1 year.
GOMEKLI: Submit diagnosis documentation and oncology or neurology prescribing; coverage is 5 years.
GRALISE: Submit diagnosis, age, and supporting documentation; coverage is 5 years.
Growth hormone: Submit diagnosis, height, weight, growth history, and confirmed growth-hormone deficiency testing; screen for contraindications; endocrinology or nephrology prescribing is required; coverage is 3 years.
HADLIMA: Submit diagnosis, concurrent medications, prior therapy and response, specialty documentation, and frequency-escalation justification; coverage is 1 year.
MAVYRET: Submit weight, genotype, HCV RNA, fibrosis level, and treatment history; prescribing must be by a hepatologist or infectious-disease specialist; approve 8–24 weeks consistent with AASLD-IDSA guidance.
Hereditary angioedema therapies: HAEGARDA, icatibant, and SAJAZIR require confirmed HAE and allergist/immunologist prescribing; confirm age-specific criteria and continuation response for icatibant; coverage is 1 year.
HETLIOZ/tasimelteon: Submit diagnosis, sleep log or wrist-activity-monitor evidence, sleep study excluding sleep apnea and periodic limb movement disorder, and sleep-specialist or neurologist prescribing. Continuation requires increased nighttime sleep and reduced daytime naps; coverage is 1 year.
HUMULIN R U-500: Confirm age and indication.
HYRNUO: Confirm age and indication.
IBRANCE: Submit diagnosis, prior therapies and treatment history, and oncology prescribing; coverage is 1 year.
IBTROZI: Confirm age appropriate under FDA prescribing information.
ICLUSIG: Submit the requested indication and supporting clinical information.
IDHIFA/IDHIFA: Submit diagnosis and clinical documentation; prescribing must be by or in consultation with a hematologist/oncologist; coverage is 5 years.
IMBRUVICA: Submit diagnosis and clinical documentation; prescribing must be by an oncologist, hematologist, or transplant specialist; coverage is 1 year.
IMKELDI: Submit diagnosis, treatment history including contraindications, age, and clinical documentation; prescribing must be by or in consultation with an oncologist, hematologist, allergist, or dermatologist; coverage is 5 years.
IMPAVIDO: Submit leishmaniasis diagnosis and specialist documentation; confirm age.
INBRIJA: Submit Parkinson disease diagnosis, prior therapy and response, neurologist prescribing, and continuation response to levodopa inhalation; coverage is 3 years.
INCRELEX: Submit IGF-1 level and laboratory documentation.
TOBI PODHALER: Submit diagnosis and clinical documentation; prescribing must be by an infectious-disease specialist or pulmonologist; coverage is 1 year.
INLURIYO: Confirm age appropriate under FDA prescribing information and submit indication documentation.
Step Therapy
Step Therapy and Prerequisites
Document prerequisite therapy before requesting products subject to step therapy. Include drug names, duration, outcomes, intolerance, contraindications, or the clinical rationale for an exception.
Topical therapy: Diclofenac 3% gel requires prior 5% fluorouracil and 5% imiquimod unless an exception applies. Adapalene requires failure, intolerance, or contraindication to tretinoin; photoaging use is excluded. ADBRY requires at least one topical corticosteroid and one topical immunomodulator for atopic dermatitis, with prior-treatment evidence.
Antidepressants and antipsychotics: MDD products such as AUVELITY, FETZIMA, TRINTELLIX, vilazodone, and related products require two generic antidepressants from different classes. EXXUA requires two generic antidepressants, one of which must be vilazodone. Antipsychotic products require treatment history with an appropriate generic atypical antipsychotic or rationale alternatives are unsuitable; MDD augmentation requires a generic antidepressant combined with quetiapine, olanzapine, or aripiprazole. COBENFY requires failure of two atypical antipsychotics.
ARIKAYCE: For initial therapy, document failure to obtain negative MAC sputum cultures after at least 6 months of multidrug background therapy.
BENLYSTA: Document inadequate response to two standard therapies at recommended doses, such as corticosteroids, antimalarials, NSAIDs, or immunosuppressants.
BESREMI: Document intolerance, contraindication, or treatment failure with prerequisite therapy.
BONSITY/FORTEO: Document a trial and failure of an oral bisphosphonate, or a parenteral bisphosphonate when oral therapy is GI-intolerable, followed by denosumab when required. Sequential osteoporosis therapy is required, and no PTH/PTHrP analog may be combined with another osteoporosis agent.
BOSULIF and BRIVIACT: Document required prerequisite therapy and treatment response; continuation of BOSULIF requires response plus CBC and liver-function results.
CIBINQO: Submit required prerequisite therapy and failure or intolerance documentation.
CINQAIR: Document severe asthma, current inhaled and/or oral corticosteroid treatment, and the required asthma testing and eosinophil evidence.
COSENTYX: For arthritis, document a trial of or contraindication to one nonbiologic DMARD. For plaque psoriasis, document failure of cyclosporine and methotrexate for at least 3 months. For hidradenitis suppurativa, document one other therapy. Every-four-week dosing must fail before every-two-week dosing is approved.
CORLANOR: Document maximally tolerated beta-blocker therapy or a contraindication; heart-failure cardiovascular criteria must also be met.
Dronabinol: For cancer-related weight loss, document megestrol failure or intolerance; pain treatment is excluded.
DUPIXENT: For atopic dermatitis, document a topical immunomodulator trial, except it is not required under age 2. For chronic rhinosinusitis with nasal polyps, document at least 12 weeks of inflammatory persistence and a 4-week intranasal corticosteroid trial. For asthma, document inhaled corticosteroid plus at least two additional controller classes and eosinophil count. For eosinophilic esophagitis, document biopsy with at least 15 eosinophils/HPF and symptoms after an 8-week topical esophageal corticosteroid trial. AFRS requires eosinophilic mucin and fungal culture.
ENBREL: Do not combine with another biologic or JAK inhibitor. RA requires a 3-month Hadlima trial unless an applicable exception applies. Plaque psoriasis and PsA require Hadlima and Yesintek trials for at least 3 months, with pediatric exceptions. JIA/JRA, GVHD, Behçet disease, uveitis, and other indications require the applicable conventional, biologic, TNF-inhibitor, corticosteroid, or immunosuppressive prerequisite; continuation requires response. Additional quantity requires plaque psoriasis, stabilized twice-weekly dosing for specified arthritis conditions, or at least 2 months of 50 mg once-weekly use.
EPIDIOLEX: For Lennox-Gastaut syndrome, document valproate and lamotrigine use and outcomes. For Dravet syndrome, document valproate and topiramate use and outcomes. For refractory seizures, document failure or intolerance of two anticonvulsants from different classes.
Dihydroergotamine: For migraine, document failure of two formulary triptans from different formulations, one oral and one nasal or injectable, unless contraindicated.
ERLEADA: For metastatic CRPC or CSPC, document abiraterone failure, intolerance, or contraindication.
FOTIVDA: Submit prior therapy and outcome; continuation requires response to tivozanib.
FRUZAQLA: Document prior colorectal-cancer treatment with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, anti-VEGF therapy, and anti-EGFR therapy when RAS wild-type and medically appropriate.
GABARONE: Gabapentin cannot be used as the required alternative unless intolerance, contraindication, or a medical reason is documented.
GATTEX: Document prior therapies and responses and complete the required pre-treatment malignancy evaluation before initiation.
TRULICITY: Document type 2 diabetes and A1C. Cardiovascular-risk use requires ASCVD or high cardiovascular risk plus the required prior therapy; weight-loss use is excluded.
IBRANCE: A trial of Kisqali or Verzenio is required before approval, except for PIK3CA-mutated HR-positive/HER2-negative locally advanced or metastatic breast cancer.
IMKELDI: Document required prerequisite treatment and any contraindication to prior therapy.
INBRIJA: Document failure of both immediate-release and extended-release carbidopa/levodopa and at least one additional Parkinson disease drug, with intent to continue treatment.
Gaucher disease: Miglustat is reserved for patients for whom enzyme-replacement therapy is not an option.
Growth hormone: Confirm deficiency with appropriate testing and screen for contraindications before initiating replacement therapy.
Documentation Required
Required Clinical Documentation
The PA submission must contain condition-specific clinical evidence, laboratory results, treatment history, and continuation response when required. Incomplete diagnosis, laboratory, specialist, or response documentation may delay or prevent approval.
Diagnosis and testing: Provide the diagnosis and applicable confirmatory testing for AAT deficiency, Lambert-Eaton syndrome, MAC lung disease, Attruby indications, Ayvakit GIST or AdvSM, Cystadrops corneal cystine crystals, Duvyzat genetically confirmed DMD, Gaucher disease, Gavreto RET fusion, Hernexeos HER2 mutation, HAE, leishmaniasis, and all oncology products requiring disease or mutation confirmation.
Laboratory evidence: Include baseline A1-PI, eosinophil count and FEV1 for severe-asthma biologics, ECG/electrolytes/TSH for Caprelsa, CBC/LFT for Bosulif, platelet count for Doptelet and Ayvakit, A1C for Trulicity, IGF-1 for Increlex, hemoglobin and iron studies for ESAs, and DXA, calcium, phosphorus, renal, alkaline-phosphatase, albumin, vitamin D, and urine calcium testing for Bonsity/Forteo.
Clinical records: Submit medical records supporting diagnosis, prior treatment, treatment response, relevant adverse effects, contraindications, and continuation response. This applies to ADBRY, AKEEGA, ALUNBRIG, FIRDAPSE, ARIKAYCE, BENLYSTA, BONSITY, BOSULIF, BRIVIACT, COBENFY, COSENTYX, DUPIXENT, ENBREL, EPIDIOLEX, EPOGEN, FOTIVDA, FYCOMPA, GATTEX, HETLIOZ, IBRANCE, IDHIFA, IMBRUVICA, IMKELDI, IMPAVIDO, INBRIJA, TOBI PODHALER, and the other products listed in this request.
AKEEGA: Provide diagnosis documentation showing metastatic malignant prostate cancer, castration resistance, and deleterious or suspected deleterious BRCA mutation, plus clinical documentation supporting the request.
ALUNBRIG: Provide approved-test documentation of ALK-positive metastatic NSCLC and evidence of prior therapy for continuation.
FIRDAPSE: Provide electrodiagnostic and anti-P/Q-type VGCC antibody evidence confirming Lambert-Eaton syndrome.
APREPITANT: Include chemotherapy drug, dose, frequency, regimen, and indication; for PONV include the rationale for using aprepitant instead of preferred ondansetron and indicate whether Part B or Part D coverage is requested.
ARIKAYCE: Include sputum culture and clinical records documenting MAC disease, multidrug regimen history, and failure to clear cultures after at least 6 months.
AYVAKIT: Include diagnosis and PDGFRA mutation evidence for GIST or platelet evidence greater than 50 × 109/L for AdvSM.
BENLYSTA: Include autoantibody testing, diagnosis, standard-therapy history, and response; exclude severe active lupus nephritis or active central-nervous-system lupus when applicable.
BONSITY: Include fracture history, prior-therapy response, DXA and pretreatment laboratory testing, and documentation that combination osteoporosis therapy is not being used.
CINQAIR and FASENRA: Include severe-asthma history, controller medications, emergency visits or hospitalizations, allergen testing, FEV1, eosinophil count, and specialist assessment.
COSENTYX and ENBREL: Include diagnosis, concurrent medications, prior therapies and reasons for failure, TB testing where applicable, treatment response, and quantity or frequency rationale. Confirm no concurrent biologic or JAK-inhibitor therapy.
DUPIXENT: Include indication-specific records: AFRS culture and eosinophilic mucin; CRS duration and nasal-steroid trial; asthma eosinophils and combination-controller history; prurigo nodularis diagnosis; or EoE biopsy and corticosteroid-trial documentation.
EPIDIOLEX and seizure therapies: Include antiseizure drug names, duration, failure or intolerance, and continuation response. For topiramate oral solution, provide prior treatment and response or contraindication.
EPOGEN/ESA therapy: For initiation, provide hemoglobin below 10 g/dL, adequate iron stores, and exclusion of iron, folate, B12, hemolytic, gastrointestinal, occult-bleeding, and underlying hematologic causes. For renewals, submit indication-specific hemoglobin, chemotherapy or zidovudine information, dose changes, and measurable response.
Forteo/Bonsity: Include fracture and BMD history, failed bisphosphonate and denosumab therapy where required, and all pretreatment laboratory results.
FOTIVDA and FRUZAQLA: Include previous therapies and outcomes; FRUZAQLA records must establish the required metastatic colorectal-cancer treatment history.
GATTEX: Include diagnosis, prior therapy and response, colonoscopy with polyp removal for adults, or pediatric fecal-occult-blood evaluation when applicable; document the required pre-treatment evaluation and discontinue for intestinal malignancy.
HETLIOZ: Include sleep logs, wrist-activity-monitor data, sleep study results, diagnosis-specific records, and continuation response showing improved nighttime sleep and reduced daytime naps.
IBRANCE: Include diagnosis, prior treatment history, and Kisqali or Verzenio trial unless the PIK3CA exception applies.
IDHIFA, IMBRUVICA, IMKELDI, and IMPAVIDO: Include diagnosis-specific clinical documentation and the required hematology/oncology, transplant, allergy/dermatology, or infectious-disease specialist records.
INBRIJA: Include Parkinson diagnosis, prior carbidopa/levodopa and other Parkinson-drug trials, response, and continuation intent.
INCRELEX: Include IGF-1 laboratory documentation and growth-related records.
TOBI PODHALER: Include pulmonary or infectious-disease clinical records supporting the diagnosis and treatment request.
AAT deficiency and growth hormone: Include phenotype or deficiency confirmation, baseline levels, height/weight and growth measurements, and relevant contraindication screening.
Denial Risk
Denial Risks and Operational Rules
Requests may be denied when an exclusion, prohibited combination, unmet prerequisite, inappropriate indication, missing specialist, or unsupported dose or site-of-care condition applies. Verify these operational requirements before submitting or renewing authorization.
Combination-therapy exclusions: Do not request BENLYSTA with another biologic, COSENTYX or ENBREL with another biologic or JAK inhibitor, DUPIXENT or FASENRA with another biologic, or HAE prophylaxis with duplicate injectable and oral formulations. Do not combine BONSITY or Forteo/teriparatide with another PTH/PTHrP analog or other osteoporosis agent.
CINQAIR site of care: Reslizumab must be administered in a specialized setting by an experienced clinician able to manage anaphylaxis; self-administration is not covered.
Diacomit: Monotherapy for Dravet syndrome is excluded.
Dronabinol: Pain treatment is excluded; cancer-related weight-loss requests require megestrol failure or intolerance.
ERIVEDGE: Do not approve when the patient is a candidate for surgery or radiation.
TRULICITY: Weight-loss use is excluded; submit diabetes evidence and cardiovascular-risk criteria when applicable.
Caprelsa: A history of congenital long-QT syndrome is an exclusion; required ECG, electrolyte, and TSH monitoring must be documented.
Age and dosing: Confirm FDA-label age for ACTIMMUNE, ARCALYST, AUGTYRO, BRUKINSA, CIBINQO, CRESEMBA, DAYBUE, ENSACOVE, ENVARSUS XR, FILSUVEZ, FINTEPLA, HETLIOZ, HUMULIN R U-500, HYRNUO, IBTROZI, IMKELDI, IMPAVIDO, INBRIJA, and INLURIYO. Patients aged 65 and older requesting cyclobenzaprine require additional criteria. Weekly or every-two-week biologic dosing requires documented failure of the less-intensive schedule when specified.
Specialist requirements: Verify the required specialist before submission, including pulmonology for AAT deficiency, neurology for FIRDAPSE, EPIDIOLEX, FYCOMPA, and INBRIJA, ophthalmology/corneal specialty for CYSTADROPS, cardiology for ATTRUBY and CORLANOR, oncology or hematology for oncology products, gastroenterology for GATTEX, sleep medicine or neurology for HETLIOZ, and infectious disease or pulmonology for ARIKAYCE and TOBI PODHALER.
Oncology prerequisites and oversight: AKEEGA requires oncology or urology prescribing; ALUNBRIG, CABOMETYX, CALQUENCE, CAPRELSA, COMETRIQ, COTELLIC, ERIVEDGE, FRUZAQLA, IBRANCE, IDHIFA, IMBRUVICA, and related agents require the stated oncology or hematology prescriber. Requests may be denied if the required prescriber specialty is absent.
Insulin and diabetic supplies: Alcohol pads, gauze, insulin needles, and syringes require confirmation that the supply is directly associated with insulin administration. Trulicity requires documented type 2 diabetes and recent A1C.
ESA exclusions: Uncontrolled hypertension and pure red-cell aplasia beginning after ESA treatment are exclusions. Apply the applicable CMS review and indication-specific renewal requirements.
Growth hormone: Do not approve when contraindications are present or growth-hormone deficiency is unconfirmed.
HAE: Do not cover duplicate hereditary-angioedema prophylaxis; verify age and confirmed HAE and document favorable response for continued icatibant.
Gabapentin: GABARONE requires a documented intolerance, contraindication, or medical reason gabapentin cannot be used; gabapentin ER products require diagnosis and age documentation.
Arikayce and Cinqair: Missing MAC sputum records, multidrug treatment history, severe-asthma evidence, eosinophil data, or required administration setting creates a denial risk.
Quantity and continuation: Approve continuation only when the requested product has documented clinical response where required, including Bosulif, Briviact, Enbrel, Epidiolex, Fotivda, Hetlioz, INBRIJA, and HAE acute-treatment products. Additional quantity or step-up dosing requires failure of the lower-frequency regimen or the specific clinical exception.
Indication exclusions and missing prerequisites: Deny or pend requests lacking required diagnosis, mutation, laboratory, prior-treatment, specialist, or response evidence; this includes AAT deficiency, AKEEGA, ALUNBRIG, AYVAKIT, BONSITY, COBENFY, CORLANOR, DUPIXENT, EPOGEN, FRUZAQLA, GATTEX, GAVRETO, HERNEXEOS, IBRANCE, IDHIFA, IMBRUVICA, IMKELDI, IMPAVIDO, INBRIJA, INCRELEX, and TOBI PODHALER.
Continuation and coverage periods: Apply the product-specific duration: 1 year for many biologics, respiratory agents, and supportive therapies; 3 years for COBENFY, GATTEX, HAE-related annual products as specified, and INBRIJA; 5 years for many oncology products and EPIDIOLEX; 2 years for Bonsity/Forteo; and the shorter durations specified for fidaxomicin, Doptelet, or aprepitant.
Submission correction: Resolve incomplete or fragmented source fields before adjudication. A request is not complete when the diagnosis, indication, prior-treatment outcome, specialist, age, laboratory evidence, coverage route, or continuation response is missing.
ESA laboratory requirementsPre-treatment hemoglobin less than 10 g/dL; adequate iron stores defined as ferritin more than 100 mcg/L or serum transferrin saturation greater than 20%; IGF-1 level is required for INCRELEX, with no numeric threshold stated
Fruzaqla eligible colorectal cancer population; csDMARDThe eligible Fruzaqla population has metastatic colorectal cancer previously treated with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, anti-VEGF therapy, and, when RAS wild-type and medically appropriate, anti-EGFR therapy. csDMARD means conventional synthetic DMARD.
HAE; HER2 mutation; non-24-hour sleep-wake disorderHAE means hereditary angioedema. A HER2 (ERBB2) tyrosine kinase domain activating mutation is a molecular alteration required for the Hernexeos diagnosis. Non-24-hour sleep-wake disorder requires a wrist-activity-monitor sleep log supporting the diagnosis and a sleep study ruling out sleep apnea and periodic limb movement disorder.